vTv Therapeutics'.

PositionTRIAD BRIEFS: HIGH POINT

vTv Therapeutics' stock price plummeted by more than 65% in early April after disclosing disappointing results of its experimental Alzheimer's medication clinical trial. The medicine was aimed at delaying...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT